Clinical Trial

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Name: Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies — clinical trial record (NCT03838926)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2019-02-11; most recent amendment 2026-03-12.

Trial Details

NCT Number	NCT03838926
Lead Sponsor	Vanda Pharmaceuticals
Conditions	Relapsed or Refractory Hematologic Malignancies
Enrollment	42 participants
Start Date	2018-09-27
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-16